RESEARCH HIGHLIGHTS
Dermatology
The twists and turns of tumor treatment
A melanoma drug is linked to long-term changes in the tumor environment in a subset of tumors that respond effectively to the drug
Melanoma is a form of skin cancer which is curable if treated early enough. Advanced melanoma is often treated with the tumor cell-killing drug dacarbazine, but only a few tumors respond to the treatment. Understanding why chemotherapy induces tumor shrinkage in some patients but not others is essential to improve therapeutic treatment. Now, an international team of researchers, including groups
from the Singapore Immunology Network and the Bioinformatics Institute at A*STAR, have identified gene expression changes that are linked to a beneficial response to dacarbazine in melanoma patients1
. The researchers obtained melanoma lesions from 13 patients
both before and after treatment with dacarbazine, and examined the genes that were expressed in those lesions. A small subset of those lesions appeared to respond to the drug, either by shrink- ing or by stopping their growth. From this analysis, the team could observe which types of genes tended to be expressed in the lesions that responded to the drug, and could therefore identify the cellular processes that were linked to a beneficial outcome in the patients. The extracellular matrix (ECM) is a network of proteins
found on the outside of cells that maintains their arrangement and organization. The researchers found that the expression of genes involved in ECM remodeling, such as secreted protein acidic and rich in cysteine (SPARC), is increased in melanoma lesions that responded to dacarbazine (see image), but not in lesions that did not respond to the drug. Immune cell infiltration into tumors can indicate the activation of an immune response, which can contribute to cancer eradication. The team observed that the expression of genes and proteins linked to immune cell invasion and activation, such as tumor necrosis factor (TNF) and CD8, were upregulated in melanoma lesions that responded to dacarbazine, but were unchanged or decreased in lesions that did not respond. Patients whose melanoma lesions experienced increases in the expression of genes linked to the immune response or to ECM remodeling tended to live longer than patients whose tumors did not exhibit these changes. “Scientists previously
A*STAR RESEARCH OCTOBER 2011– MARCH 2012 A microscopic image of melanoma tumor cells expressing SPARC
hypothesized that the mechanism of action of chemotherapy may not be limited to direct toxicity on tumor cells, and we demonstrate here for the first time that this is indeed the case for dacarbazine,” explains Alessandra Nardin, the first author of the paper. The findings can aid in the understanding of how to
combine other therapies, such as immune cell transfer, with dacarbazine to boost the beneficial response it can elicit in melanoma patients.
■
1. Nardin, A. et al. Dacarbazine promotes stromal remodeling and lymphocyte infiltration in cutaneous melanoma lesions. Journal of Investigative Dermatology 131, 1896–1905 (2011).
7
From Ref. 1 © 2011 A. Nardin
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96